ELIGLUSTAT TARTRATE: Glucosylceramide Synthase Inhibitor Treatment of Type 1 Gaucher Disease

Overview

Journal Drugs Future

Publisher Thomson Reuters

Specialty Pharmacology

Date 2012 May 8

PMID 22563139

Citations 52

Authors

J A Shayman

Affiliations

Soon will be listed here.

Abstract

Eliglustat tartrate (Genz-112638) is a novel, orally administered agent currently in development for the treatment of lysosomal storage disorders, including type 1 Gaucher disease and Fabry disease. This glucosylceramide analogue acts as an inhibitor of glucosylceramide synthase, a Golgi complex enzyme that catalyzes the formation of glucosylceramide from ceramide and UDP-glucose and is the first step in the formation of glucocerebroside-based glycosphingolipids. Pre-clinical pharmacological studies demonstrate that the agent has a high therapeutic index, excellent oral bioavailability and limited toxicity. Phase I studies in healthy volunteers revealed limited toxicity with an excellent pharmacodynamic response, as measured by decreased plasma glucosylceramide concentrations. Phase II studies in patients with type 1 Gaucher disease have demonstrated promising clinical responses, as measured by decreases in spleen size, improvement in hemoglobin concentrations and increased platelet counts. Two randomized phase III trials testing the efficacy and safety of eliglustat tartrate are currently in progress.

Citing Articles

Targeting sphingolipid metabolism in chronic lymphocytic leukemia.

Nguyen Van Long F, Le T, Caron P, Valcourt-Gendron D, Sergerie R, Laverdiere I Clin Exp Med. 2024; 24(1):174.

PMID: 39078421 PMC: 11289351. DOI: 10.1007/s10238-024-01440-x.

A Novel Cytotoxic Mechanism for Triple-Negative Breast Cancer Cells Induced by the Type II Heat-Labile Enterotoxin LT-IIc through Ganglioside Ligation.

King-Lyons N, Bhati A, Hu J, Mandell L, Shenoy G, Willison H Toxins (Basel). 2024; 16(7).

PMID: 39057951 PMC: 11281474. DOI: 10.3390/toxins16070311.

Bioinformatics to Identify Biomarkers of Diabetic Nephropathy based on Sphingolipid Metabolism and their Molecular Mechanisms.

Ning Y, Zhou X, Wang G, Zhang L, Wang J Curr Diabetes Rev. 2024; 21(2):e070524229720.

PMID: 38712372 DOI: 10.2174/0115733998297749240418071555.

Drug Repurposing and Lysosomal Storage Disorders: A Trick to Treat.

Mele B, Rossetti F, Cubellis M, Monticelli M, Andreotti G Genes (Basel). 2024; 15(3).

PMID: 38540351 PMC: 10970111. DOI: 10.3390/genes15030290.

GBA Regulates EMT/MET and Chemoresistance in Squamous Cell Carcinoma Cells by Modulating the Cellular Glycosphingolipid Profile.

Clark L, Dickinson A, Lima S Cells. 2023; 12(14).

PMID: 37508550 PMC: 10378370. DOI: 10.3390/cells12141886.

References

Charrow J, Andersson H, Kaplan P, Kolodny E, Mistry P, Pastores G . The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med. 2000; 160(18):2835-43. DOI: 10.1001/archinte.160.18.2835. View

RADIN N, Arora R, Ullman M, Brenkert A, Austin J . A possible therapeutic approach to Krabbe's globoid leukodystrophy and the status of cerebroside synthesis in the disorder. Res Commun Chem Pathol Pharmacol. 1972; 3(3):637-44. View

Natoli T, Smith L, Rogers K, Wang B, Komarnitsky S, Budman Y . Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models. Nat Med. 2010; 16(7):788-92. PMC: 3660226. DOI: 10.1038/nm.2171. View

Barton N, Furbish F, Murray G, Garfield M, Brady R . Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc Natl Acad Sci U S A. 1990; 87(5):1913-6. PMC: 53594. DOI: 10.1073/pnas.87.5.1913. View

Hatch S, Archer J, Gummuluru S . Glycosphingolipid composition of human immunodeficiency virus type 1 (HIV-1) particles is a crucial determinant for dendritic cell-mediated HIV-1 trans-infection. J Virol. 2009; 83(8):3496-506. PMC: 2663285. DOI: 10.1128/JVI.02249-08. View

Shayman J, Lee L, Abe A, Shu L . Inhibitors of glucosylceramide synthase. Methods Enzymol. 1999; 311:373-87. DOI: 10.1016/s0076-6879(00)11097-3. View

Koprivica V, Stone D, Park J, Callahan M, Frisch A, Cohen I . Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease. Am J Hum Genet. 2000; 66(6):1777-86. PMC: 1378059. DOI: 10.1086/302925. View

Abe A, Arend L, Lee L, Lingwood C, Brady R, Shayman J . Glycosphingolipid depletion in fabry disease lymphoblasts with potent inhibitors of glucosylceramide synthase. Kidney Int. 2000; 57(2):446-54. DOI: 10.1046/j.1523-1755.2000.00864.x. View

Brumshtein B, Greenblatt H, Butters T, Shaaltiel Y, Aviezer D, Silman I . Crystal structures of complexes of N-butyl- and N-nonyl-deoxynojirimycin bound to acid beta-glucosidase: insights into the mechanism of chemical chaperone action in Gaucher disease. J Biol Chem. 2007; 282(39):29052-29058. DOI: 10.1074/jbc.M705005200. View

10.

Abe A, Gregory S, Lee L, Killen P, Brady R, Kulkarni A . Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation. J Clin Invest. 2000; 105(11):1563-71. PMC: 300859. DOI: 10.1172/JCI9711. View

11.

Grabowski G . Gaucher disease: gene frequencies and genotype/phenotype correlations. Genet Test. 1997; 1(1):5-12. DOI: 10.1089/gte.1997.1.5. View

12.

Mignot C, Doummar D, Maire I, de Villemeur T . Type 2 Gaucher disease: 15 new cases and review of the literature. Brain Dev. 2006; 28(1):39-48. DOI: 10.1016/j.braindev.2005.04.005. View

13.

Abe A, Inokuchi J, Jimbo M, Shimeno H, NAGAMATSU A, Shayman J . Improved inhibitors of glucosylceramide synthase. J Biochem. 1992; 111(2):191-6. DOI: 10.1093/oxfordjournals.jbchem.a123736. View

14.

Sanchez-Olle G, Duque J, Egido-Gabas M, Casas J, Lluch M, Chabas A . Promising results of the chaperone effect caused by imino sugars and aminocyclitol derivatives on mutant glucocerebrosidases causing Gaucher disease. Blood Cells Mol Dis. 2009; 42(2):159-66. DOI: 10.1016/j.bcmd.2008.11.002. View

15.

Lukina E, Watman N, Arreguin E, Banikazemi M, Dragosky M, Iastrebner M . A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood. 2010; 116(6):893-9. PMC: 2924227. DOI: 10.1182/blood-2010-03-273151. View

16.

RADIN N . Treatment of Gaucher disease with an enzyme inhibitor. Glycoconj J. 1996; 13(2):153-7. DOI: 10.1007/BF00731489. View

17.

Abe A, RADIN N, Shayman J, Wotring L, Zipkin R, Sivakumar R . Structural and stereochemical studies of potent inhibitors of glucosylceramide synthase and tumor cell growth. J Lipid Res. 1995; 36(3):611-21. View

18.

Zhou S . Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet. 2009; 48(12):761-804. DOI: 10.2165/11318070-000000000-00000. View

19.

Lee L, Abe A, Shayman J . Improved inhibitors of glucosylceramide synthase. J Biol Chem. 1999; 274(21):14662-9. DOI: 10.1074/jbc.274.21.14662. View

20.

Weinreb N, Aggio M, Andersson H, Andria G, Charrow J, Clarke J . Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients. Semin Hematol. 2004; 41(4 Suppl 5):15-22. DOI: 10.1053/j.seminhematol.2004.07.010. View